EPO: Plants which are not patentable

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO: Plants which are not patentable

Sponsored by

inspicos-400px recrop.jpg
Young plant tree sprout in woman hand. Concept of farming and environment protecting.

The Enlarged Board of Appeal of the EPO (EBA) has recently issued opinion G 3/19, which concludes that plants and animals exclusively obtained by “essentially biological processes” are exempt from patentability. This finding only affects patents derived from patent applications filed after July 1 2017.

Summary

Article 53(b) of the European Patent Convention (EPC) exempts 1) plant and animal varieties and 2) essentially biological processes for the production of plants and animals from patentability. In 2015, the EBA concluded in its consolidated decisions G 2/12 and G 2/13 that this exemption did not extend to products of such methods. Since July 1 2017, Rule 28(2) EPC has provided that under Article 53(b) of the EPC, plants obtained exclusively from an essentially biological process are also exempt from patentability. However, in 2018, a Technical Board of Appeal held in its controversial decision T 1063/18 that new Rule 28(2) EPC conflicted with Art. 53(b).

The president of the EPO in 2019 referred a point of law to the EBA concerning the interpretation of Article 53(b) of the EPC.

The EBA initially endorsed its earlier decisions on the matter. But in contrast to the Board deciding T 1063/18, the EBA found that in the time after Decisions G2/12 and G2/13 the meaning of Article 53(b) could change. Consequently, the EBA now holds that introduction of Rule 28(2) EPC and its implementation throughout Europe is a development that provides for a new interpretation of Art. 53(b), namely that plants obtained from essentially biological processes are exempted. Somewhat uniquely, the EBA set a cutoff date for the new interpretation of July 1 2017, meaning that any European patent application pending on that date and seeking protection for plants obtained from essentially biological processed is not affected by the new interpretation.

Peter Koefoed

more from across site and SHARED ros bottom lb

More from across our site

King & Spalding has now hired 15 partners from Winston Taylor and legacy firm Winston & Strawn in offices spanning Texas, San Francisco, and Chicago
Firm says its work with a biotech client could signal a sea change in how - and when - law firms enter the drug development process
Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
Gift this article